Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Targeting angiogenesis as a promising modality for the treatment of prostate cancer

Jianqing Lin1, William K Kelly

  • 1Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Jianqing.lin@jefferson.edu

The Urologic Clinics of North America
|October 23, 2012
PubMed

Insights

Antiangiogenic therapy shows promise for prostate cancer treatment by targeting tumor blood vessel growth. Novel strategies and combination approaches are key for future clinical success in managing this disease.

Area of Science:

  • Oncology
  • Vascular Biology

Background:

  • Antiangiogenic therapy is effective against solid tumors.
  • Prostate cancer treatment has explored various antiangiogenic strategies.
  • These include targeting proangiogenic factors and signaling pathways.

Purpose of the Study:

  • To review general concepts of tumor angiogenesis.
  • To examine clinical trials of antiangiogenic agents in prostate cancer.
  • To discuss novel biologics and combination approaches.

Main Methods:

  • Literature review of tumor angiogenesis.
  • Analysis of key clinical trials involving antiangiogenic agents.
  • Examination of monoclonal antibodies, small molecule inhibitors, and immunomodulatory agents.

Main Results:

  • Antiangiogenic therapy has demonstrated success in solid tumors.
  • Multiple strategies are being investigated for prostate cancer.
  • Clinical trials highlight the potential of these agents.

Conclusions:

  • Targeting angiogenesis remains a promising strategy for prostate cancer.
  • Rational trial design and combination therapies are crucial.
  • Novel biologics offer further therapeutic avenues.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...